Clinical Trial

An Efficacy and Safety Study of Sodium Oligomannate (GV-971) for the Treatment of Alzheimer's Disease

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The primary purpose of this study is to confirm the clinical efficacy and mechanism of action of GV-971, and identify incidence of known adverse reactions in long-term use and observe new adverse reactions, providing more guidance for clinical use.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-06-08.
Status change: Not Yet Recruiting → Recruiting 2023-11-08
Trial Details
NCT Number NCT05908695
Lead Sponsor Green Valley (Shanghai) Pharmaceuticals Co., Ltd.
Conditions Alzheimer's Disease
Enrollment 1,312 participants
Start Date 2023-08-31
Primary Completion 2029-06 (estimated)
Study Completion 2029-12 (estimated)
Updated on ClinicalTrials.gov 2023-11-09